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Table. 1-Year Cardiac Events for the Overall Population and Subsets of the ION
U.S. Post-Approval Registry
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All ION Registry
patients
(N¼1111)
9.4% (97/1028) 2.0% (21/1028) 3.0% (31/1028) 6.8% (70/1028) 2.1% (22/1028)
Combined Subsets From the ION and TE-PROVE Registries
PERSEUS-like
patients
(n¼622)
4.9% (25/594) 0.7% (4/594) 1.2% (7/594) 4.0% (24/594) 1.2% (7/594)
Medically
treated diabetes
(n¼635)
10.3% (61/594) 2.2% (13/594) 2.2% (13/594) 8.4% (50/594) 1.7% (10/594)
Insulin-treated
(n¼247)
11.9% (27/226) 3.1% (7/226) 1.3% (3/226) 10.2% (23/226) 0.9% (2/226)
Lesion Length
28mm
(n¼477)
8.6% (39/452) 1.1% (5/452) 2.9% (13/452) 6.6% (30/452) 2.4% (11/452)
Reference
vessel2.5mm
(n¼610)
9.7% (56/576) 1.9% (11/576) 2.4% (14/576) 7.6% (44/576) 2.1% (12/576)
Bifurcation
Lesions
(n¼281)
9.9% (27/272) 1.5% (4/272) 2.6% (7/272) 6.6% (18/272) 0.7% (2/272)
Total Occlusion
(n¼246)
8.1% (19/235) 0.4% (1/235) 3.4% (8/235) 6.4% (15/235) 2.1% (5/235)
Overlapping
Stents
(n¼369)
9.9% (35/353) 0.6% (2/353) 4.8% (17/353) 7.1% (25/353) 2.3% (8/353)
Unstable
Angina
(n¼797)
8.1% (60/742) 1.5% (11/742) 2.3% (17/742) 6.1% (45/742) 1.6% (12/742)
MACE¼major adverse cardiac events (deﬁned as CD, MI, and TVR); CD¼cardiac death;
MI¼myocardial infarction; TVR¼target vessel revascularization; ARC ST¼Academic Research
Consortium deﬁnite/probable stent thrombosis.
By prespeciﬁcation, subset analyses combine the ION and TE-PROVE populations. Binary
rates.
aION protocol deﬁnition
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Background: The TE-PROVE post-market registry is evaluating clinical outcomes
for patients receiving the third-generation, paclitaxel-eluting, platinum chromium
TAXUS Element stent (Boston Scientiﬁc, Natick, MA) over 5 years in a real-world
setting. This is the ﬁrst report of results from this large multicenter registry.
Methods: This was a prospective, open-label, multicenter observational 'all-comers'
study that included 1014 patients at 37 sites in Europe. Follow-up was at 30 days, 6
months, and 1 year, and will continue annually through 5 years. The primary endpoint
was the overall and TAXUS Element stent-related target vessel failure rate (TVF,
deﬁned as cardiac death, and target vessel-related myocardial infarction [MI] and
reintervention [TVR]) at 1 year post-implantation. Secondary endpoints included the
components of TVF, all-cause mortality, and ARC deﬁnite/probable stent thrombosis.
Results: Among 1014 enrolled patients, 1-year clinical follow-up or death occurred in
97.3% (987/1014) of patients. Patients were 75.0% male (760/1014), mean age was
65.110.8 years, 25.5% had medically treated diabetes (259/1014), and 10.7% (109/
1014) were treated for STEMI. At baseline, mean lesion length among 1299 treated
lesions was 19.812.0 mm and mean reference vessel diameter was 3.10.5 mm.
At 1 year, the rate of TVF (primary endpoint) was 6.0% (59/987), of which 3.7%
(37/987) was considered related to the study stent. Cardiac death was 0.7% (7/987),
target vessel-related MI was 1.1% (11/987), and TVR was 4.7% (46/987). All-cause
death occurred in 1.2% (12/987) patients and ARC deﬁnite/probable ST was 0.5% (5/
987). Additional outcomes for subsets, including small vessels, long lesions, and
diabetes, will be available at the meeting.
Conclusions: The primary endpoint results from the TE-PROVE registry demonstrate
good performance and safety for the TAXUS Element paclitaxel-eluting stent at 1 year
in everyday clinical practice.
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Background: There are limited data for comparing the safety and efﬁcacy of ever-
olimus-eluting stent (EES) versus zotarolimus-eluting stents (ZES-R) for long-term
follow-up. This study evaluated the safety and efﬁcacy of these two stents in real-
world practice for 3-year of follow-up.
Methods: 926 patients who treated with EES (Xience V, Abbott Vascular, USA; n
¼459) and ZES-R (Endeavor Resolute, Medtronic Cardiovascular, USA; n ¼ 467)
were analyzed using single center registry from 2008 to 2010 after excluding the
patients with cardiogenic shock at admission and the patients with in-hospital
mortality for reducing the potential selection bias. Primary endpoint was a composite
of any death, any myocardial infarction, and target vessel-revascularization at 3-year
of follow-up.
Results: ZES-R group was younger (64.5  10.8 year vs. 66.0  10.2 year, p ¼
0.033) then EES group but other baseline characteristics and laboratory ﬁndings were
similar between two groups. EES was more used for left main lesion (9.8% vs. 3.9%, p
< 0.001) but ZES-R was more used for right coronary artery (30.3% vs. 41.3%, p <
0.001). Although implanted number of stent was not different between two groups,
EES was larger in diameter (3.11  0.42 mm vs. 3.06  0.40 mm, p ¼ 0.026) and
shorter in length (40.2  24.7 mm vs. 45.3  25.7 mm, p ¼ 0.002) compared with
ZES-R. Discharge medication was not different between two groups. During 3-year of
follow-up (920  206 days in EES group vs. 900  216 days in ZES-R group, p ¼
0.152), primary endpoint was not different between two groups (14.4% in EES group
vs. 16.3% in ZES-R group, p ¼ 0.466). Stent thrombosis was similar between two
groups (0.9% vs. 1.3%, p ¼ 0.387).
Conclusions: In this real-world registry with unrestricted use of EES and ZES-R, two
new generation drug-eluting stent showed comparable safety and efﬁcacy during long-
term follow-up.B58 JACC Vol 62/18/Suppl B j October 27–November 1, 2013TCT-180
One-Year “Real-World” Outcomes Following Implantation of the ION
Paclitaxel-Eluting Platinum Chromium Coronary Stent in Routine Clinical
Practice: Primary Endpoint Results of the ION U.S. Post-Approval Registry
Louis Cannon1, Carey D. Kimmelstiel2, Mirle Kellett3, Anthony White4, Roger Hill5,
Timothy Grady6, Paul R. Myers7, Paul Underwood8, Keith D. Dawkins9
1McLaren Northern Michigan, Petoskey, MI, 2Tufts Medical Center, Boston,
Massachusetts, 3Maine Medical Center, Portland, ME, 44. NEA Baptist Memorial
Hospital, Jonesboro, AR, 5St. Bernards Medical Center, Jonesboro, AR, 6Aspirus
Heart and Vascular Institute - Research and Education, Wausau, WI, 77. Centennial
Heart and Vascular, Nashville, TN, 8Boston Scientiﬁc, Marlborough, MA, 9Boston
Scientiﬁc Corporation, Marlborough, MA
Background: The ION Registry assessed clinical outcomes for the thin-strut, ION
(TAXUS Element) Paclitaxel-Eluting Platinum Chromium Coronary Stent System
(Boston Scientiﬁc, Natick, MA) in unselected patients. This is the ﬁrst report of results
from this large multicenter registry.
Methods: This prospective, open-label registry enrolled the ﬁrst 1120 consenting
patients treated with the ION stent for any indication at 40 clinical sites in the United
States. Follow-up was at discharge, 30 and 180 days, and annually to 5 years. The
primary endpoint was the 1-year rate of cardiac death or MI in PERSEUS-like patients
(JACC 2010;56:264–71). Per protocol, the primary endpoint result from the ION
registry was also combined with the European post-approval registry (TE-PROVE),
which enrolled 306 PERSEUS-like patients, and the PERSEUS WH/SV populations
(N¼1166).
Results: 1111 patients received a study stent, 316 were PERSEUS-like, and 1-year
follow-up was 92.1% (1023/1111). Most patients were male (70.3%, 781/1111) with
a mean age 64.111.0 years. At 1 year, the primary endpoint of CD/MI occurred in
2.1% (6/292) of PERSEUS-like patients in ION and 2.3% (40/1729) patients in the
combined analysis. The upper 1-sided 95% CI for the combined analysis was 2.9%,
which was signiﬁcantly less than the prespeciﬁed performance goal of 7.6%
(P<0.001). Secondary endpoints and subsets are given in the Table.Conclusions: The 1-year results of the ION U.S. Post-Approval Study conﬁrm the
safety and effectiveness of the ION stent for the treatment of coronary artery disease in
everyday clinical practice.j TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
